Core Viewpoint - Ying Sheng Science (00209.HK) proposes a rights issue to raise up to approximately HKD 182 million by issuing up to 1,299,962,832 rights shares at a price of HKD 0.14 per share, representing a discount of about 23.5% from the last closing price of HKD 0.183 [1] Summary by Categories Rights Issue Details - The company plans to issue a maximum of 1,299,962,832 rights shares to eligible shareholders, with each existing share entitling the holder to one rights share [1] - The estimated net proceeds from the rights issue, assuming full subscription, will be approximately HKD 176.5 million [1] Use of Proceeds - Approximately HKD 116.6 million (about 66.0% of the net proceeds) is intended for loan repayment, covering both principal and interest [1] - About HKD 59.9 million (approximately 34.0% of the net proceeds) will be allocated for general working capital of the group [1]

Core Viewpoint - The company reported its Q3 2025 results, indicating a revenue of 51.886 million HKD, a gross profit of 6.523 million HKD, and a post-tax profit of 1.706 million HKD [1] Financial Performance - Revenue for Q3 2025 was 51.886 million HKD [1] - Gross profit stood at 6.523 million HKD [1] - Post-tax profit amounted to 1.706 million HKD [1] Fundraising Activities - The company is considering a rights issue to support business recovery and strengthen its financial position, pending approval from the Stock Exchange and review results [1] - An independent underwriter has fully underwritten a rights issue at a price of 0.045 HKD per share, offering a 1-for-4 rights issue to raise approximately 150 million HKD [1]